RAPT Therapeutics, Inc. (RAPT) NASDAQ
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
RAPT Therapeutics, Inc.
Address
561 Eccles Avenue
South San Francisco, CA 94080
United States of America (the)
Phone
650 489 9000
Website
Sector
Healthcare
Industry
Biotechnology
Employees
67
First IPO Date
October 31, 2019
Key Executives
| Name | Title | Pay | Year Born |
| Brian Russell Wong | Chief Executive Officer, President & Director | 1.05M | 1972 |
| Dirk G. Brockstedt | Chief Scientific Officer | 490,250 | 1969 |
| William | Strategic Consultant | 709,582 | 1966 |
| Rodney K. Young | Chief Financial Officer, Principal Accounting Officer & Secretary | 716,004 | 1963 |
| Nipun Davar | Senior Vice President of Technical Operations | 0 | 1968 |
| Paul Kassner | Senior Vice President of Biology | 0 | 1967 |
| Steve Young | Vice President of Technology | 0 | N/A |
| Gwen R. Carscadden | Chief Human Resources Officer | 0 | 1961 |
| Michael Listgarten | General Counsel | 0 | N/A |
| Jennifer Nicholson | Senior Vice President of Regulatory Affairs & Quality Assurance | 0 | N/A |
Description
RAPT Therapeutics, Inc. is a clinical-stage biopharmaceutical firm specializing in immunology. The company is dedicated to discovering, developing, and commercializing innovative oral small molecule therapies. These treatments are aimed at addressing critical unmet medical needs for patients battling oncology and inflammatory diseases. Its primary drug candidate for inflammation, RPT193, functions as a C-C motif chemokine receptor 4 (CCR4) antagonist. This compound works by selectively preventing type 2 T helper cells from migrating into inflamed tissues. In the oncology pipeline, FLX475 stands as the company's leading candidate, also an oral small molecule CCR4 antagonist. This therapy is currently undergoing Phase 1/2 clinical trials to evaluate its efficacy both as a standalone treatment and in combination with pembrolizumab for individuals with advanced cancer. RAPT Therapeutics is also engaged in the development of a hematopoietic progenitor kinase 1 (HPK1) inhibitor. Founded in 2015, the company initially operated as FLX Bio, Inc. before rebranding as RAPT Therapeutics, Inc. in May 2019. Its corporate headquarters are situated in South San Francisco, California.
